Login / Signup

Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis).

Christopher Sj ProbertShaji SebastianDaniel R GayaP John HamlinGillian GillespieAnita RoseHelen TateColin WheelerPeter M Irving
Published in: BMJ open gastroenterology (2018)
NCT02092285; 2013-004583-56.
Keyphrases
  • ulcerative colitis
  • open label
  • clinical trial
  • early onset
  • squamous cell carcinoma
  • randomized controlled trial
  • phase ii study
  • radiation therapy
  • double blind
  • locally advanced